AF

Aimei Health Technology Co., Ltd

AFJKFinancial ServicesNASDAQ

Shell Companies · Last scanned Jul 22, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$0
Net Income
$1.1M
-58.5% YoY
EBITDA
-$835,759
+21.5% YoY
Free Cash Flow
$192,794

Scan Results

Daily timeframe
6 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 15 RSI OversoldRSI 15.6, below 30, stock may be oversold
Jul 14 RSI OversoldRSI 17.9, below 30, stock may be oversold
About Aimei Health Technology Co., Ltd

Aimei Health Technology Co., Ltd does not have significant operations. At a $38.0M market cap, Aimei Health Technology Co., Ltd ranks as a micro-cap company within financial services. It intends to effect a merger, share exchange, asset acquisition stock purchase, reorganization, or similar business combination with one or more businesses.

Where AFJK stands vs its 150-day and 200-day moving averages

As of the July 15, 2026 close, AFJK finished 70.88% below its 150-day moving average ($40.15) and 64.52% below its 200-day moving average ($32.95). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is AFJK overbought or oversold?

At the July 15, 2026 close, AFJK's RSI(14) was 15.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$38.0M
P/E (TTM)80.00
EPS$0.15
Beta0.55
52W Change+7.6%
Analysis

On the balance sheet, AFJK has $19K in cash with $2.1M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $193K in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing.

With a beta below 0.7, Aimei Health Technology Co., Ltd typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. At over 50x earnings, AFJK carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Aimei Health Technology Co., Ltd and its sector.

Links
More Financial Services stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms